Join to View Full Profile
Ucla Med CardioBox 951679, Bh-307 ChsLos Angeles, CA 90095
Phone+1 310-825-5280
Are you Dr. Honarpour?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Narimon Honarpour, MD is a cardiologist in Los Angeles, California. He is currently licensed to practice medicine in California.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 2005 - 2010- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Texas Southwestern Medical SchoolClass of 2003
Certifications & Licensure
CA State Medical License 2005 - 2024
Publications & Presentations
PubMed
- 49 citationsA GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.Murielle M Véniant, Shu-Chen Lu, Larissa Atangan, Renee Komorowski, Shanaka Stanislaus
Nature Metabolism. 2024-02-01 - 23 citationsEvaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.Hannes Helgason, Thjodbjorg Eiriksdottir, Magnus O Ulfarsson, Abhishek Choudhary, Sigrun H Lund
JAMA. 2023-08-22 - 9 citationsThe effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).Tor Biering-Sørensen, Masatoshi Minamisawa, Jiankang Liu, Brian Claggett, Alexander Papolos
European Journal of Heart Failure. 2021-04-07
Authored Content
- Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing CardiovascularAugust 2020
- Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing CardiovascularAugust 2020
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent MyocardialMay 2020
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent MyocardialMay 2020
- Join now to see all
Press Mentions
GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual DiseaseJanuary 11th, 2021
